Technology thesis · Biotechnology & Health
low conviction conceptBioprinting
Bioprinting stays pre-commercial for solid organs through 2030 and ships commercial volume only for tissue models and dermal applications, with FDA Modernization Act 2.0 expanding the drug-screening demand.
Position maintained continuously · last reviewed Jun 3, 2026
The thesis
State of the art (2026)
Bioprinting in 2026 is a commercial research-tools business wrapped around a still-preclinical therapeutic ambition. BICO Group (CELLINK), the category leader with over 30 per cent share, posted roughly $152M trailing revenue to end-2025 after a 2024 restructuring that cut staff and refocused on consumables and tissue models. The therapeutic frontier sits with Aspect Biosystems, which in January 2026 absorbed Novo Nordisk’s stem-cell islet and hypoimmune assets to lead a bioprinted islet replacement for type 1 diabetes – still IND-enabling, not in clinic. No bioprinted solid organ has FDA approval. The real near-term pull is FDA Modernization Act 2.0 demand for human tissue models that displace animal toxicology screens.
CELLINK BICO Group + Aspect commercial revenue sustains category economically
BICO Group (CELLINK) posted roughly $152M trailing revenue to end-2025 from bioprinters, bioinks and tissue models. Aspect Biosystems raised a $115M Series B in January 2025 (plus a 2026 Canadian government grant). Commercial revenue from tissue models, dermal and drug-screening services sustains the category economically while solid-organ therapeutics stay preclinical.
Aspect Biosystems islet programme is the leading therapeutic bioprinting bet
Aspect’s bioprinted islet for type 1 diabetes restores glucose control without chronic immunosuppression. Funded via the Novo Nordisk partnership ($75M initial 2023, up to $650M per-product milestones); in January 2026 Aspect took over Novo’s stem-cell islet and hypoimmune assets to lead development as Novo retreats from cell therapy. Still IND-enabling. Validates the bioprinted-cell-therapy pathway if it reaches clinic.
FDA Modernization Act 2.0 (Dec 2022) drives tissue-model drug-screening adoption
Same regulatory pull as organoids. Animal testing no longer mandatory. Major pharma (Genentech, AstraZeneca, Vertex, BMS) adopting bioprinted tissue models for tissue-toxicity screening. Parallel growth with organoid adoption.
Everything below is live inside CanaryIQ
The full analysis behind the verdict — the structure is real; the content unlocks when you log in.
Signal stack
Evidence stacked leading → lagging
Technology-native KPIs
Metrics that predict trajectory, tracked over time
Landscape map
Who builds what — and who depends on whom
Catalyst calendar
Dated events that will move the position
Technology roadmap
Milestones on the path to maturity
Watchlists
Companies, people and papers — each with a remove-by condition
Decision frameworks
The same call, framed for your desk
Thesis changelog
When our view changed, and why
Change our mind
5 disconfirming conditions
The rest is inside
You've read the verdict. The file is much deeper.
The full signal stack, technology-native KPIs tracked over time, the landscape of who depends on whom, the dated catalyst calendar, decision frameworks for every desk, live watchlists and the changelog of every time our call on Bioprinting has changed — all live inside CanaryIQ.